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ABSTRACT

Neelam Shinde. M.S., Department of Microbiology and Immunology,
Wright State University, 2012. Establishment of a quiescent infection of HSV-1 in L929
fibroblasts using a mitotic inhibitor and IFN-.

The goal for this study was to determine if a quiescent infection of HSV-1 could be
induced in murine fibroblasts L929 by treating them with the anti-mitotic agent 5-fluoro
2’deoxy uridine (FUDR) alone and with interferon-. Since neurons are post-mitotic and
exhibit a lower metabolic rate than other cells, fibroblasts were treated with FUDR to
induce a post-mitotic state. The cell cycle arrest of fibroblasts would decrease the
thymidylate metabolism and impair HSV-1 replication. An evaluation of cytopathic
effects of FUDR was used to determine the optimal concentration which arrests cell
growth and inhibits viral replication. Image J program developed by NIH was used to
analyze images of cultured L929 cells. In initial experiments cells showed protection
from cytopathic effects of HSV-1 when treated with FUDR and IFN-. To determine
whether the virus was in a quiescent state in L929 cells attempts were made to rescue
viable virus from these cells. The FUDR+ IFN- + HSV-1 treated L929 cells were cocultured with Vero cells or lysate from L929 cells was added to Vero cells. Viral plaques
indicating viral rescue were observed after 48hrs.of incubation by staining the cells with
crystal violet, indicating that HSV-1 was in a silent state in these treated L929 cells.
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Hoechst staining was performed to detect the apoptosis in the cells treated with FUDR
and IFN-. Approximately one third of the population of treated L929 cells showed
protection against viral apoptosis compared to virus infected control at 12 hrs. postinfection. No difference was observed at 6 hrs. post- infection. RT-PCR analysis was
conducted at 6, 10 and 16 hrs. post infection with HSV-1 at 2 multiplicity of infection to
detect expression of ICP0 (infected cell protein) and LAT (Latency associated transcript)
viral transcripts. LAT expression was observed at 16 hrs. in the infected control.
Immuno-staining was used to detect HSV-1 ICP0 protein in treated L929 cells and virus
infected control. A significant difference was observed, with higher expression of ICP0 in
virus infected control than in cells treated with FUDR and IFN. Image J was used to
merge images of actin stained and ICP0 stained cells. In these asynchronous fibroblast
cultures treated with FUDR about 5- 10% cells replicate in the presence of FUDR.
Four percent of the cells in the FUDR treated population showed ICP0 staining, as
expected. A quiescent infection of HSV-1 was established in L929 cells treated with the
mitotic inhibitor and maintained in a medium supplemented with IFN-. LAT was not
detected in treated cells.
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INTRODUCTION
Herpes Simplex Virus (HSV) is a double stranded DNA virus that belongs to
Herpesviridae family. It infects its host through both lytic and latent infection. HSV-1
and -2 usually infect via the oral or genital mucosa and replicate in the stratified
squamous epithelium. The virus enters into the sensory nerve fibers via the stratified
squamous epithelium and then by retrograde transport to the cell body of the neuron in
the dorsal root ganglion (DRG), adjacent to the trigeminal ganglion (Cunningham et al.,
2006). In these sensory ganglia, HSV establishes a lifelong persistent infection (latency).
However, reactivation of the virus may occur due to physical or emotional stress or UV
irradiation, causing recurrent disease (Johnson et al., 2008). HSV-1 establishes latency in
the sensory neurons, namely trigeminal ganglia (Perng et al., 2009). During latency the
viral replicative functions are shut down and infectious virus particles are not detected
(Bloom et al., 2010).
HSV-1 latency is a complex virus host interaction the molecular basis of which is not
well understood. Neuron, virus and the host immune system together play a role in
regulating and maintaining latency of HSV-1 (Toma et al., 2008). Type I interferons
(IFN-α and IFN-β) act as the first line of defense against many viral infections. IFN-
Type II interferon, prevents HSV-1 reactivation by inhibiting the immediate early gene
ICP0 (Mossman et al., 2010). As a defense mechanism, HSV-1 exerts an anti-interferon
effect by activating the protein suppressor of cytokine signalling-1(SOCS-1) as seen in
1

infected keratinocytes (Frey et al., 2009). In contrast, the fibroblast cell line L929 pretreated with IFN- was protected against HSV-1 with a minimal increase in SOCS-1.
IFN-α can induce a quiescent HSV-1 infection in porcine trigeminal ganglia neurons
(Regge et al., 2010). A quiescent infection of HSV-1 in cultured cells could provide an
important means of studying the molecular aspects of in vivo latency (Mcmohan et al.,
2008). We proposed to develop a model system wherein we could mimic the environment
of a neuronal cell and study HSV-1 infection cycle. Fibroblasts cell lines were chosen for
the study based on the earlier observations by Frey et al., 2009.

The hypothesis of this study was that a quiescent infection of HSV-1 could be
induced in murine fibroblasts (L929 and A.2R.1) by treating them with anti-mitotic
agent FUDR and IFN-.

Fibroblast cell lines were treated with varying concentrations of FUDR to determine the
lowest effective concentration required to induce a post-mitotic state. Lytic HSV-1
infection was demonstrated by cytopathic effects (CPE) and quiescent infections were
monitored for inhibition of CPE. Nuclear staining was performed to determine if L929
cells treated with FUDR and IFN-γ were being protected from apoptosis after infection
with HSV-1. As LAT is the only viral transcript produced during the latent state of HSV1 (Bloom et al., 2010), RT-PCR was used to determine the presence of LAT in these cells
under the defined experimental conditions. When the virus enters a latent state the genes
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for lytic infection are not transcribed (Bloom et al., 2010). Immunofluorescence staining
was used to detect HSV-1 ICP0 protein indicative of replicating virus.
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LITERATURE REVIEW
HSV-1 INFECTION CYCLE:
HSV-1 can establish both productive and latent infections. Productive infection with
HSV-1 leads to formation of epithelial lesions such as cold sores (Jackson et al., 2003).
HSV-1 is known to infect about 60-80% people worldwide (Cunningham et al., 2006). It
causes encephalitis and ocular herpes which is a major cause of blindness in the Western
world (Cunningham et al., 2006). Virus attaches to the host cell surface by envelope
glycoproteins gC, gB, gD, gH and gL. Glycoproteins gE and gI are involved in cell-cell
dissemination (Rajcani et al., 2000) (Fig1). After entry into the cell, the nucleocapsid
associates with transporter protein dynein and reaches the nuclear pore (Dodding et al.,
2011). Dynein is a molecular motor associated with microtubules (cytoskeletal filaments)
and is involved in the retrograde transport of HSV-1 to the cell body of neuron
(Diefenbach et al., 2008). However, Kinesins are another type of motor proteins
associated with microtubules involved in the anterograde transport of HSV-1 the from the
neuronal cell body towards axon tips (Diefenbach et al., 2008).
Viral replication in the nucleus occurs in association with localized complexes nuclear
domain 10 (ND10) and promyelocytic leukemia associated bodies (PML) (Rajcani et al.,
2000). HSV-1 genes are grouped into three kinetic classes (α, β, ) based on their time of
expression in a lytic cycle. The alpha genes are the immediate early genes α 0, α 4, α 27,
α 22 and α 22 (1-2 hpi and maximum protein synthesis at 2-4 hpi), β-early or delayed
3

early (3-7 hpi) and gamma are late genes. The major immediate early proteins necessary
for lytic events are infected cell protein (ICP0, 4, and 27) (Rajcani et al., 2000). ICP0 and
ICP4 are viral trans-activators for expression of early and late genes.

Figure 1: HSV-1 attachment and entry into host cell (Adapted from
http://darwin.bio.uci.edu/~faculty/wagner/hsv4f.html).

IMMUNE RESPONSE TO HSV-1
Host immune response mediated by CD8+ and CD4+ T-cells plays a crucial role in
limiting the virus at initial stages or later by preventing reactivation. Using a murine
4

model of genital infection, Johnson and his colleagues (2008) showed that CD4+ T cells
are involved in clearance of HSV-1 from sensory ganglia and spinal cords. CD4+ T cells
are also essential for priming of CD8+ T-cells during primary response to HSV-1
infection (Rajasagi et al., 2009). CD8+ T-cells are the cytotoxic effector cells in HSV-1
infection and they control infection by exocytosis of lytic granules or by secretion of
cytokines IFN- and TNF-α (Sheridan et al., 2007). CD8+ T-cells also control the
maintenance of latency and prevent reactivation of HSV-1. In ex-vivo cultures of latently
infected ganglia, IFN- and granzyme B secreted by CD8+ T cells inhibited HSV-1
reactivation by degrading ICP4 protein (crucial for lytic events) (Knickelbein et al.,
2008).

INTERFERON RESPONSE
IFN- exerts its effects through IFN- receptor (IFNGR) composed of two subunits
IFNGR-1 and IFNGR-2. When a homodimer of IFN- binds to the receptor complex,
JAK2 gets phosphorylated and it transphosphorylates JAK1. IFN- receptor is in turn
phosphorylated promoting binding and activation of STAT1. IFN-/IFNGR1/STAT1
complex is internalised and translocated to nucleus where it binds to interferon response
element of target gene (Eriksen S. E., 2005). SOCS-1 is an inhibitor of janus kinase
activity (Vuong et al 2004) and downregulates IFN- expression in keratinocytes (Frey et
al., 2009). IFN-α 1 plasmid transfection of mouse fibroblasts L929 lead to reduced viral
load and viral gene expression (Noisakran et al., 2000). Treatment of human fibroblast
(FB) cells with β and gamma interferon in combination and individually inhibits
5

replication of HSV-1 (Peng et al., 2007). Similar observations were made by Sainz and
Halford (2002) using Vero cells pre-treated with IFN-α, β and gamma and then infected
with HSV-1. Thus IFN- is effective in limiting HSV-1 infection. In neuronal cells CD8+
T-cells, which are a major source of cytokine IFN-, persist at the site and therefore
prevent virus replication or reactivation from latency (Hendricks et al., 2005).
Despite effective immune response by the host against HSV-1, it survives in the host.
Virus tries to evade these immune mechanisms by counteracting IFN α/β signaling.
ICP27 protein of HSV-1 in detectable amounts in cells leads to secretion of heat stable,
protease sensitive IFN-α antagonizing protein which negates the effects of IFN-α
(Johnson et al, 2010). ICP0 also counteracts STAT 1-mediated interferon protection,
thereby permitting lytic infection.

LATENCY AND REACTIVATION
HSV-1 latency is characterized by down-regulation of lytic phase genes as the genome
enters a circular form and persists in a non-replicative state in the neuronal cells (Fig 2).
Although sensory neurons provide a permissive environment for viral replication, HSV-1
is able to establish latency in a few neuronal cells (Thompson et al., 2001). Latent
infections are characterized into three phases: establishment, maintenance and
reactivation. Establishment of latency results from restricted viral gene expression which
may depend upon the host cell type. As the HSV-1 genome persists in a quiescent state in
neurons, low level of replication may occur to maintain the virus (Wagner and Bloom.,
1997). The latent state is characterized by absence of detectable HSV-1 antigen, minimal
6

transcription of productive cycle genes, and high expression of latency-associated
transcripts (LATs) in a subpopulation (one third) of infected neurons (Millhouse et al.,
2000). Reactivation of virus occurs under conditions of stress or due to immune
incompetence which results in detectable amounts of infectious virus particles in the host
(Wagner and Bloom., 1997).
Latency associated transcript (LAT) is the only major transcript produced during latency,
other viral products can be detected during establishment of latency. ICP4 transcripts
were found in mouse ganglia latently infected with HSV-1 (Coen et al., 1995). Inman,
Perng and colleagues (2001) demonstrated that LAT promotes survival of neuronal cells
(N2A) transfected with plasmid expressing LAT. Similar observations were made by
Thompson et al., (2001). The major reason for survival of the latently infected neurons
may be due to the role of LAT in preventing apoptosis of cells. ICP0 plays a critical role
in modulating the lytic-latent cycle of HSV-1. ICP0 promoter activity is repressed in the
presence of IFN- in latently infected trigeminal ganglia neurons (Hendricks et al., 2005).

LAT prevents viral induced apoptosis in neuronal cells (Perng et al., 2000). Peng et al.,
(2002) showed that LAT inhibits caspase-8 and caspase-9- induced apoptosis in neuro 2A
cells. Since several small regions of LAT sequence are in antisense configuration to
ICP0, LAT may also influence reactivation of HSV-1 to some extent. Two types of LAT
transcripts 1.5kb and 2.0kb are detected in cultures of trigeminal ganglia. 2 kb LAT
transcript was detected in ex-vivo cultures of trigeminal ganglia (Hill et al., 1996,
Deshmane et al., 1993).

7

Figure 2: Molecular features of HSV-1 lytic and latent infections (Adapted from
Bloom et al., 2010).

CHROMATIN STATE DURING LATENCY
Epigenetic control regulates lytic and latent events (Bloom et al., 2010). Viral genome
forms an episomal structure inside neuronal cell nucleus and LAT is the only transcript
produced in this state. Lytic genes remain in the transcriptionally repressed form. LAT is
associated with acetylated histone H3, a euchromatin marker; while the lytic genes
ICP0/ICP4 are associated with heterochromatin markers (Bloom et al., 2010). Chromatin
associated with LAT is found to be facultative and thus it changes state during
reactivation.
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MODELS TO DEMONSTRATE LATENCY
Latent infection has been studied in animal models such as mice, rabbit and guinea pig.
Latent infections were established but reactivation is not achieved successfully in these
models (Wagner et al., 1997). Stringent animal safety protocols and cost of maintenance
limit the use of animal models. Studying the expression of genes during latent phase and
the genome structure in that state could be carried out effectively in a cell-culture model.
Various cell culture models have been established to study latency of HSV-1. A long
term quiescent infection of HSV-1 was established in rat pheochromocytoma (PC12)
cells following differentiation with nerve growth factor (Su et al., 1999). Quiescent
infection of HSV-1 was established in normal human diploid fibroblasts by McMohan
and Walsh., (2008). The cells were serum starved and elevated temperature (40.50C) was
used to maintain the virus in a dormant state.

Vierbuchen et al., (2010) converted fibroblasts to functional neurons by transfecting them
with lentiviruses expressing neural-lineage specific transcription factors Ascl1, Brn2, and
Myt1l. Similarly, a successful effort was made by Yoo and his colleagues (2011) using
micro-RNA to convert fibroblasts to neuronal cells. Human primary fibroblasts are
preferred cells over keratinocytes or lymphoid cells to study latency due to their lower
metabolic state more closely resembling the neurons (Hancock et al., 2006). Murine L929
fibroblasts are also used to study HSV-1 latency as they are susceptible to the cytopathic
effects of HSV-1 and show protection when transfected with an IFN-α construct (Harle et
al., 2002).

9

Since sensory neurons are post-mitotic cells and cellular proteins required for HSV-1
replication are not synthesized viral replication is impaired in these cells. Therefore, the
treatment of fibroblasts with a mitotic inhibitor (FUDR) to limit cell cycle progression
was our goal in the present study. Auer et al., (1970) showed that only 10% of the
population L929 cells from an asynchronous culture replicated in the presence of FUDR.
Cells were arrested into G1 and early S-phase. The cell cycle time for L929 cells in
culture is approximately 30 hrs. and at this time about 80-90% cells are in G1 and Sphases (Dolznig et al., 2004). Petrowsky et al., 2001 demonstrated that replication of wild
type HSV-1 was impaired in the presence of 10nM of FUDR. PC-12 cells differentiated
with nerve-growth factor and FUDR survived infection with HSV-1 (Moxley et al.,
2002).

MODE OF ACTION OF 5-FLUORO 2-DEOXY URIDINE (FUDR):
Roobol et al., 1989 studied the metabolic pathway and target of 5-fluoro 2-deoxy uridine
in L1210 leukemia cells. 5-fluoro 2-deoxy uridine is transported through the cell
membrane and becomes phosphorylated to FdUMP which binds to thymidylate
synthetase and inhibits DNA synthesis leading to cell cycle arrest in the S-phase. In nonreplicating neurons in the central nervous system there is low level of thymidylate
metabolism (Lee et al., 1991). FUDR also acts as a substrate for thymidine kinase which
converts it to FdUMP which inhibits DNA synthesis (Figure 3). The wild type strains of
HSV-1, including HSV-1 Syn 17+ used in the present study, are capable of producing
enough thymidine kinase to replicate (Lee et al., 1991). Wild type HSV-1 strain F
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showed impaired replication in the presence of FUDR (Petrowsky et al., 2001). The
action of FUDR on murine L929 cells was studied by Auer et al., (1970), who found that
DNA synthesis was blocked in early G1 and early S-phases. Approximately 10% of cell
population replicated even in the presence of FUDR (18 hrs.) which might be the cells in
late S or early G2 phase. FUDR is a drug of choice due to its reversible nature. This was
demonstrated in a study by Roobol et al., (1984) who found that inhibitory effect of
FUDR can be reversed by addition of thymidine. Dubbs and Kit (1964) showed that
FUDR (0.01 µg/ml) mediated inhibition of L-M cells treated for 6 or 24 hrs. was reversed
by an exogenous supply of thymidine.

11

Figure 3: Metabolic pathways and targets of fluoro-pyrimidines. Stars indicate
targets of 5-fluoro 2-deoxy uridine –thymidylate synthetase and thymidine kinase.
(Adapted from Roobol et al., 1989).

12

MATERIALS AND METHODS
CELL LINESL929 (CCL-1, ATCC) fibroblast cells (clone of L strain derived from the connective
tissue of C3H mouse).
Vero cells (CCL-81, ATCC).
The cell lines were cultured in a standard medium prepared from Dulbecco’s Modified
Eagles Medium (DMEM) supplemented with 10% heat inactivated bovine calf serum and
gentamicin solution (50 µg/ml of medium). Cells were grown and maintained in 100mm²
cell culture plates and incubated at 37⁰C and 5% CO2 in a humidified incubator.
Maintenance medium was prepared from DMEM plus 2% calf serum. Growth medium
and culture plates were purchased from Fisher Scientific, Pittsburgh, PA.
Virus:
Herpes Simplex Virus-1 strain Syn 17+ (Dr.Nancy Sawtell, Children’s Hospital Medical
Center, Cincinnati, OH) was propagated in the lab. Vero cells were grown in 75cm² flask
and confluent monolayer was infected with HSV-1 at 0.1 multiplicity of infection (moi).
Cells were examined and harvested along with medium when cytopathic effect (cells
were rounded and detached from the bottom of the flask) was evident 3-5 days postinfection. Medium was stored as virus stock in 100 ul aliquots at -80⁰C. Plaque assay was
performed using Vero cells to titrate the virus.
13

Anti-mitotic agent:
FUDR (Fisher scientific, Pittsburgh). A stock solution was prepared in sterile distilled
water at concentration of 1mg/ml and maintained at 2 to 8⁰C for 2 weeks. Dilutions were
freshly made prior to use.
Nerve growth factor- β (Sigma Aldrich) was stored at -20⁰C in 10 ul aliquots.
Interferon-gamma- Dilutions (25 to 200 units/ml) were prepared in maintenance medium.

Cytopathic effects (CPE) assay:
An assay was performed to analyze cytopathic effects of HSV-1 on cells pre-treated with
5-fluoro 2’deoxy uridine (FUDR) and interferon gamma (IFN- ). Two different
protocols were used to perform the assay.
Protocol 1:
Cells were plated on 96, 12 or 48 well cell culture plates at a seeding density of 2.5 X 104
to 3.0 X 104 cells/ml as per experimental requirement and grown overnight in DMEM
with 10% calf serum. The assay was performed using L929 cells initially. Cells at 7080% confluence were treated with 5-fluoro 2’ deoxy uridine at concentrations ranging
from 160 µg/ml to 5 µg/ml of medium plus nerve growth factor-β (100 ng/ml) for 2 days.
Cells were rinsed with maintenance medium (Frey et al., 2009) and treated with
interferon-gamma at 100, 75, 50 and 25 units/ml for 24 hrs. Post IFN-  treatment cells
were infected with HSV-1 at multiplicity of infection of 0.1 and incubated for 2 hours
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(time for virus adsorption) at 370C. After 2 hours the medium containing residual virus
was aspirated and cells were incubated at 370C for 48 hrs. in DMEM with 10% calf
serum. Dilutions of FUDR, IFN- and HSV-1 were prepared in DMEM containing 2%
calf serum (maintenance medium). To examine the cytopathic effects after 48 hours, cells
were rinsed with phosphate buffered saline (pH 7.4), fixed with 10% formalin for 10
mins at room temperature and stained with 0.5% crystal violet for 5 mins. Plates were
rinsed with water, air dried overnight and scanned using an HP ScanJet 5300C. Scans
were analyzed by Image J program provided by National Institute of Health. Experiments
were performed in triplicates.

Protocol 2:
Slight modifications were made in the first protocol after analyzing the initial results.
L929 cells were plated in 12 well plates in 10% DMEM and allowed to grow overnight to
70-80% confluence. They were then treated with FUDR at 5 and 10 µg/ml (concentration
determined from results of first assay) for 1, 2, 3 or 6 hrs. respectively. Virus infection
was carried out at 0.1 multiplicity of infection and cells were incubated for 48 and 72 hrs.
A second experiment was run where cells treated with FUDR (treatment time was
decided based on first experiment) were maintained in medium containing IFN- at 25,
50, 75 and 100 units/ml post HSV-1 infection. Virus was dispensed at 0.1 moi in all
experiments and incubation period varied from 48 to 72 hours post infection. Dilutions of
FUDR, IFN- and HSV-1 were prepared in DMEM containing 2% calf serum (Frey et al.,
2009). Results were analyzed as per protocol1 (Page 14).

15

Rescue experiment (Plaque assay):
Based on the observations of CPE assay, about 90% of cells treated with FUDR and IFN were protected from the cytopathic effects of HSV-1 as seen by absence of viral
plaques. To determine if the virus was silenced in these cells, we performed a plaque
assay using Vero cells. Experiment was carried out using L929 cells as per protocol 2,
with a minor modification. After treating the cells with FUDR and infecting them with
HSV-1 for 48 hours, the original medium was removed from cells and Vero cells in
DMEM/10% calf serum were overlayed at a density of 0.1 X 106 cells/ml. The cells were
incubated at 370C and 5% CO2 for 24 hours. After 24 hours medium was replaced with
overlay medium containing methyl cellulose (Fisher Scientific, Pittsburgh, PA) and
incubated further for 24- 48hrs to determine plaque formation. A control experiment was
run alongside without overlaying Vero cells and plate was incubated till the end of the
rescue experiment. Both plates were stained with 0.5% crystal violet to stain the survived
cells and were scanned using HP Scan Jet 5300C. Scans were analyzed by Image J
program provided by National Institute of Health.
A second rescue experiment was performed to reconfirm the results of first rescue
experiment. L929 cells were lysed by two freeze thaw cycles and lysate was added on a
monolayer of Vero cells. After adsorption for 2 hrs. the medium containing lysate was
aspirated and fresh DMEM/10% calf serum was added to Vero cells. Plaques were
observed after 48 hrs. incubation.

16

Hoechst staining:
To determine if cells treated with FUDR were protected from apoptotic effects of HSV-1,
we performed a nuclear staining experiment. L929 cells were grown overnight on
coverslips in DMEM containing 10% calf serum in a 6 well plate. The following day
cells were treated with FUDR at 5 or 10 µg/ml for 3 hours. Cells were rinsed with
DMEM after 3 hours and infected with HSV-1 at 10 moi. Virus was incubated with the
cells for 2 hours at 37 0C. After adsorption the medium was replaced with either 10%
DMEM (for control) or 2% DMEM + IFN- (100 units/ml) and cells were incubated for
6, 8 or 12 hours at 37 0C. After incubation cells were rinsed with 1X PBS (pH 7.4) and
fixed with 1:1 methanol : acetone at -20 for 10 mins. Fixative was aspirated and cells
were rinsed with 1X PBS three times five minutes per wash. Hoechst stain was added to
the cells at 0.5 µg/ml concentration for 10 mins in dark. Finally cells were rinsed two
times with 1X PBS. The coverslips were then mounted on glass slides using mounting
medium Vectashield (Vector Labs) and then sealed with nail polish. The slides were
analyzed using fluorescence microscopy.
RT-PCR:
Cells were plated into 100mm culture dishes at seeding density of 0.1X106 cells/ml and
grown in DMEM containing 10% calf serum. At 70% confluence cells were treated with
FUDR at 5 and 10 µg/ml concentration for 3 hours. The medium was removed after
incubation, cells were washed with DMEM and fresh medium containing 10% calf serum
(for control cells) or medium containing IFN- (200 units/ml) was added and cells were
incubated at 370C for 6, 10 and 16 hours.
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RNA extraction:
RNA was extracted from cells at 6, 10, and 16hrs. post infection. RNA was isolated by
using Rneasy mini kit (Qiagen) as per manufacturer’s instructions. 50µl of RNA was
eluted and stored at -80 0C till further use. Integrity of isolated RNA was checked by
electrophoresis on 1% agarose gel. Ethidium bromide was added to the gel. RNA samples
were added in separate wells and gel was run at 95 volts. Bands were visualized under
UV light and image was captured using Fuji LAS-3000 camera.
RT-PCR:
5µl of extracted RNA was amplified using Verso one step RT-PCR kit
(Thermoscientific). A total reaction volume of 50 µl was used for 40 cycles and the
thermal cycling was program used as per manufacturer’s instructions: cDNA synthesis at
500C for 15 mins., thermostart activation at 950C 15 mins., denaturation 950C for 20 sec.,
annealing 550C for 30 sec., extension at 720C for 1 min and a final extension at 720C for
5 mins. The amplified product was resolved by agarose gel electrophoresis. 1% agarose
gel was prepared. Ethidium bromide was added in the gel which was run at 95 volts.
Bands were visualized under UV light and image was captured using Fuji LAS-3000
camera.
Immunostaining:
L929 cells were grown overnight on coverslips in DMEM containing 10% calf serum in a
6 well plate. The following day cells were treated with FUDR at 5µg/ml for 3 hours.
Cells were rinsed with DMEM after 3 hours and infected with HSV-1 at 5 moi. Virus was
incubated with the cells for 2 hours at 37 0C. After adsorption the medium was replaced
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with either 10% DMEM (for control) or 2% DMEM with or without IFN- (100 units/ml)
and cells were incubated for 4, 8 or 16 hours at 37 0C. After incubation cells were rinsed
with 1X PBS (pH 7.4) and fixed with 4% paraformaldehyde for 15 mins. Fixative was
aspirated and cells were rinsed with 1X PBS three times five minutes per wash. Cells
were then permeabilized with 0.2% tritonX for 10mins and then washed with 1X PBS
3X5 mins. After permeabilization cells were blocked with 3% BSA for 1hour at room
temperature. The primary mouse ICP0 antibody was prepared in the blocking buffer at a
dilution of 1:25000 and then it was applied to each coverslip. The coverslips were placed
in a humidified chamber cell side down and allowed to incubate at 4o C overnight.
Coverslips were transferred back to the dishes next day and washed 3 times with 0.5%
BSA. Fluorescent-labeled (FITC) secondary antibody anti-goat IgG diluted 1:100 and
Texas red conjugated phalloidin diluted 1: 100 were added to cells. Cells were allowed to
incubate for 3 hours in dark at room temperature. Coverslips were transferred back to the
dishes and washed 2 times with 0.5% BSA. Hoechst stain was added to the cells at 0.5
µg/ml concentration for 10 mins in dark. Finally cells were rinsed two times with 0.5%
BSA. The coverslips were then mounted on glass slides using mounting medium
Vectashield (Vector Labs) and then sealed with nail polish. The slides were analyzed
using fluorescence microscopy.
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RESULTS
Determining minimum effective dose of 5-Fluoro 2-deoxy uridine (cytopathic effects
inhibition assay):

Cytopathic effects assay was performed to determine the appropriate dilution of FUDR
to be used to treat cells. It was important to determine the concentration of FUDR which
would only arrest the cell cycle without causing cytotoxicity to L929 cells. In figures 4, 6,
and 8, higher concentrations of FUDR (160, 80, 40, 20, 10, and 5 µg/ml respectively) in
addition to IFN- (25, 50, 75, 100 units/ml) were added to the L929 cells. Following
infection with HSV-1 at 0.1moi only 20-25 % cell survival was observed. Viral plaques
were seen in HSV-1 infected control, but very few cells were observed in the FUDR and
IFN- treated wells. Pixel density as measured by Image J showed approximately 20%
cell survival (figures 5 and 7) with higher concentrations and about 30- 40% (fig 9)
survival with 10 or 5 µg/ml concentrations of FUDR.
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Figure 4: Effects of Fudr at higher concentration (160 and 80µg/ml) on survival of
L929 cells. Cell density was sparse in the center of the wells (3-10) treated with
FUDR and IFN-γ and infected with HSV-1. Control wells (11-12) also showed few
surviving cells. These higher concentrations of FUDR were toxic to cells and
induced cell death.
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Figure 5: Effects of Fudr at higher concentration (160 and 80µg/ml) on survival of
L929 cells. Higher concentrations induced cell death as seen by only 20-25% cells
survival. % Pixel density was normalized against uninfected control. FUDR treated
group showed significant differences in cell survival relative to HSV-1 infected
control. *P<0.001 by ANOVA. % Pixel density was used as a measure of cell
survival.
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Figure 6: Action of FUDR at 20 and 40 µg/ml on survival of L929 cells. Viral
plaques were obserevd in HSV-1 infected control (well 2). Cell density was sparse in
the center of the wells (3-10) treated with FUDR and IFN-γ and infected with HSV1. Control wells (11-12) treated with FUDR alone also showed few surviving cells.
These concentrations of FUDR were also toxic to cells similar to Fig. 4.
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Figure 7: Effects of FUDR at 20 and 40 µg/ml. FUDR was toxic to cells at these
concentrations and thus only about 10-15% cell survival was observed. % Pixel
density was normalized against uninfected control. FUDR treated group showed
significant differences in cell survival relative to HSV-1 infected control *P<0.001 by
ANOVA. % Pixel density was used as a measure of cell survival.
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Figure 8: Effect of FUDR at concentrations of 10 and 5µg/ml on survival of L929
cells. Viral plaques were observed in HSV-1 infected control (well 2). Few cells were
observed in wells treated with FUDR, IFN-γ, and HSV-1 treated wells (3 to 10)
similar to FUDR treated control (wells 11 and 12). The cell density of FUDR treated
was increased compared to higher concentrations as seen in fig 4 and 5.
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Figure 9: Effects of FUDR at 10 and 5 µg/ml. There was a little increase in cell
survival about 30-40% compared to higher concentrations in fig 5 and 7. % Pixel
density was normalized against uninfected control. FUDR treated groups showed
significant differences in cell survival relative to HSV-1 infected control *P<0.001 by
ANOVA. % Pixel density was used as a measure of cell survival.

2.5 and 1.25 µg/ml were also used, which showed improved cell survival (data not
shown). These results indicated that treatment of FUDR even at lower concentrations for
a prolonged period (2 days) lead to cell death. For subsequent experiments, 5 and 10
µg/ml concentrations were selected for shorter exposure times.
Comparison of varying exposure times of FUDR treatment:
Treatment of cells with FUDR for 2 days resulted in death of L929 cells, treatment time
was reduced to 6, 3, 2 and 1 hr. respectively (data not shown). Cytopathic assay was
performed to determine the optimum FUDR exposure time required to arrest cell growth.
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After infection with 0.1 moi of HSV-1, medium was replaced with 10% DMEM (for
control) and 2% DMEM for FUDR treated cells. Cell survival was analyzed at 48 and 72
hrs. post infection. Fewer viral plaques were observed in cells treated with FUDR for 2 or
3hrs. ( Fig 10, 12) compared to HSV-1 infected control. A higher cell density was also
seen in FUDR treated controls where treatment time was 2 or 3 hrs. (Figure 10 and 12).

Figure 10: Comparison of FUDR treatment periods on L929 cells (48 hrs. pi.). Cells
were treated with FUDR for 2, 3or 6 hrs. and then infected with HSV-1. Higher cell
density and fewer plaques were observed when cells were treated with FUDR for 2
or 3 hrs. FUDR treatment for 6 hrs. reduced the cell density by about 40-50%.

An increase in the survival of L929 cells was observed when the treatment time of FUDR
was reduced to 2 and 3 hrs. L929 cells treated with FUDR for 6 hrs. showed reduced cell
density and lower cell survival after HSV-1 infection which was similar to FUDR treated
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control cells (Fig. 10). The reason for reduced cell density for 6 hrs. treatment time may
be because of the cytotoxic effects rendered by FUDR prior to HSV-1 infection. This was
evident from fewer plaques in cells treated with FUDR.

*

*

Figure 11: Comparison of FUDR treatment periods on L929 cells (48 hrs. pi.). There
was a significant increase in the cell survival when time of FUDR treatment (10 and
5µg/ml) was reduced to 2 or 3 hrs. About 80-90% cell survival was observed in cells.
(% Pixel density was normalized against uninfected control). *P<0.05 by ANOVA.
% Pixel density was used as a measure of cell survival.
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(a)

*

*

(b)

Figure 12(a, b): Effect of varying treatment periods of FUDR on L929 cells without
IFN- (72 hrs. pi.) Treatment of L929 cells for 6 hrs. with FUDR resulted in almost
40-50% cell death. Treatment of L929 cells with FUDR for 2 or 3 hrs. showed
increased protection of cells against HSV-1. (% Pixel density was normalized
against uninfected control). Cells survival in treatment groups was significantly
increased compared to HSV-1 control even at 72 hrs. post infection (*P<0.05 by
ANOVA). % Pixel density was used as a measure of cell survival.
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Combined effect of FUDR and IFN- on survival of L929 cells after HSV-1
infection:
In the cytopathic effects assay performed with higher concentrations of FUDR (Fig 4, 6,
and 8) maximum cell death about 70% was observed. To mimic the natural infection in
neurons cells were also treated with IFN-. After treatment with FUDR for 3 hrs (time
arbitrarily selected after analyzing results in Fig. 11 and 12). Cells were infected with
HSV-1 at 0.1 moi, after adsorption for 2 hrs., the medium was replaced with 2% DMEM
supplemented with IFN- at 50, 75, 100, and 200 units/ml. Fig.13 (Frey et al., 2009).

Figure 13: Effect of FUDR (3 hrs.) and IFN- on survival of L929 cells after HSV-1
infection. Few viral plaques were observed in cells treated with FUDR and IFN-γ at
100 and 200 units/ml (wells 7 to 14) as compared to HSV-1 infected control (well 2).
L929 cells displayed protection from cytopathic effects of HSV-1 when treated with
FUDR ( 5µg/ml) for 3 hrs and maintained in IFN-γ (100 or 200 units/ml) post HSV-1
infection.
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Figure 14: Effect of FUDR (3 hrs.) and IFN- on cell survival after HSV-1 infection.
About 90% cells survival was observed after HSV-1 infection in cells treated with
FUDR and IFN-γ. % Pixel density was normalized against uninfected control.
FUDR and IFN-γ treatment groups showed significant increase in cell survival
relative to HSV-1 infected control *P<0.001 by ANOVA.
Indicates cell group
not significantly different from uninfected control. % Pixel density was used as a
measure of cell survival.
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*

Vero

Lysate from L929 + Vero

(b)

Figure 15: Virus rescue by overlaying Vero cells. Viral plaques were observed in
L929 cells overlayed with Vero cells *P= 0.004 (a) and on Vero cells to which lysate
from L929 cells was added *P<0.001 by ANOVA (b). % Pixel density was
normalized against uninfected L929 + Vero (a) and Vero (b) control cells. Viral
plaques were indicative of virus rescue from L929 cells. % Pixel density was used as
a measure of cell survival.
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HOECHST STAINING :

Figure 16: Hoechst staining to detect apoptosis at 6 hrs. post infection. L929 cells
were grown overnight on coverslips and then treated with FUDR for 3 hrs. Cells
were then infected with HSV-1 at 10 moi and then incubated in medium with IFN-.
At 6 and 12 hrs. post infection nuclear staining with Hoechst was performed. At 6
hrs. post infection no difference in nuclear morphology was observed in L929
uninfected control and FUDR + IFN-γ treated cells. Some atypical staining was
observed in both groups as indicated by arrows. Bar markers indicate 50 µm size.

No differences in nuclear morphology were evident at 6 hrs. post infection (Fig. 16).
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HOECHST staining (12 HRS POST INFECTION)

Figure 17: Hoechst staining to detect apoptosis at 12 hrs. post infection. Cells were
treated in the same way as in Fig. 16. At 12 hrs. post infection about 80-90% cells
were lysed in the virus infected control. About one third of the cells treated with
FUDR + IFN-γ survived HSV-1 induced apoptosis. Bar markers indicate 50 µm size.

About 80% cells were lysed in the HSV-1 infected control at 12 hrs. post infection.
Approximately one-third of the population of cells survived the cytopathic effects of
HSV-1 in the FUDR + IFN-γ treated group (Fig. 17). In natural HSV-1 infection neurons
are protected from apoptotic effects of HSV-1 because of the presence of LAT transcripts
(Perng et al., 2000). These observations suggest that quiescent herpes virus infection
occurred in one-third or less of the treated fibroblasts.
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Detection of latency associated transcript (LAT) and ICP0 by RT-PCR:
RT-PCR analysis was conducted to analyze expression of HSV-1 LAT in L929 cells
treated with FUDR and IFN- and infected with HSV-1 at 2 moi. Analysis was performed
at 6, 10 and 16 hours post-infection. LAT expression was observed in untreated HSV-1
infected L929 cells at 16 hours post-infection but not in cells treated with FUDR and
IFN-. No expression was seen at 6 and 10 hours (data not shown) post-infection in
control or experiment.
RT-PCR (6hrs. post infection) and 16hrs. post infection:

a

b

Figure 18: RT-PCR analysis of L929 cells at 6 (a) and 16 (b) hrs. post-infection. No
LAT expression was observed at 6 hours post infection (a). At 16 hrs. post infection
LAT expression was observed as displayed by 149 bp product (b). Arrows indicate
positions of GAPDH control (a and b) and LAT (b).
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Detection of ICP0 by immunofluorescence staining:
L929 cells treated with FUDR and IFN- were infected at 5 moi with HSV-1 and
immuno-staining with antibody against HSV-1 ICP0 protein and phalloidin against Actin
was performed at 4, 8 (data not shown) and 16 hrs. post infection. Cells were observed
under fluorescent microscope and two images were taken per field. Two different filters
were used to take images for one field because secondary antibodies used had different
fluorescent labels (FITC and Texas red). Three fields were observed for each condition
per experiment and 3 experiments were performed for each time point. Nuclear
expression of ICP0 expression was observed as fluorescent dots. Actin expression was
observed in all cells. A marked difference in the number of cells expressing ICP0 protein
was observed as expected in HSV-1 infected control and other groups. Approximately
15-17% cells in HSV-1 infected control and 4% treated cells showed ICP0 protein
expression. A difference in the morphology of cells was also observed: normal cell
morphology was maintained in at least one-half of the cells treated with FUDR and IFN-γ
compared to HSV-1 infected control. Cells in HSV-1 infected control were rounded
because of the cytopathic effects of HSV-1.
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Figure 19: HSV-1 ICP0 expression at 4 hours post-infection (Green- ICP0 staining,
Red- Actin) (a, b, c) HSV-1 control (d, e, f) L929+FUDR+HSV-1 (g, h, i) L929+
FUDR+ HSV-1+ IFN-. Nuclear expression of ICP0 was observed in HSV-1
infected control and cells treated with FUDR alone or in combination with IFN-γ.
Bar markers indicate 50 µm size.
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Figure 20: HSV-1 ICP0 expression at 16 hours post-infection (Green- ICP0 staining,
Red- Actin) (a, b, c) HSV-1 control (d, e, f) L929+FUDR+HSV-1 (g, h, i) L929+
FUDR+ HSV-1+ IFN-. Nuclear expression of ICP0 was observed in infected control
and in a few cells treated with FUDR and IFN-γ. Bar markers indicate 50 µm size.
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a. Spindle shaped cells

b. Rounded cells

c. Long projections

Figure 21: L929 cell morphology at 16 hours post-infection (Red- Actin). (a)
Uninfected control (b) HSV-1 control (c) FUDR + IFN-+ HSV-1 treated cells. Cells
treated with FUDR and IFN-gamma retained normal cell morphology as in (a) but
some cells showed longer projections (c). The cells in HSV-1 infected control (b)
were rounded due to cytopathic effects of HSV-1. Arrows are showing distinct cell
morphology. Bar markers indicate 50 µm size.

Since IFN- protected L929 cells from the viral cytopathic effects, normal cell morphology was
retained in these cells treated with FUDR and IFN-.
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DISCUSSION
HSV-1 undergoes a latent infection in a few sensory neurons (Millhouse et al. 2000).
Latent infection is characterized as a non-productive state where genes for lytic cycle are
repressed. Viral latency associated transcript is the only viral gene transcribed during this
silent state (Millhouse et al., 2000). Schang et al., (2002) suggest that sensory neurons are
post-mitotic and do not allow viral replication, in contrast to Sawtell’s contention that
sensory neurons have a permissive environment for HSV-1 replication. Schang et al.,
(2002) contend that these quiescent neurons lack cellular factors required for productive
infection. Cyclin dependent kinases (cdk) 1 and 2 are not present in quiescent neurons,
which limits replication of HSV-1 (Schang et al., 2002). Cdk 2 is required for cell cycle
progression into S phase, while cdk1 allows cell to proceed into mitosis (Schang et al.,
2002). Role of cyclin dependent kinase 5 in association with p35 in preventing HSV-1
replication was demonstrated by Haenchen et al., (2010). Cdk5 plays a role in the
adhesion, migration, and differentiation of lens and corneal epithelial cells and its activity
is, in part, regulated by p35 (Haenchen et al., 2010). Absence of p35 impairs ocular
replication of HSV-1 in mice (Haenchen et al., 2010).
In the present study FUDR was toxic at higher concentrations (160, 80, 40 20 µg/ml
respectively) concentrations as displayed by CPE. Only 20 to 30% cell survival was
observed in cells treated with FUDR due to its cytotoxic effects. As FUDR leads to
inhibition of DNA synthesis and repair, cells treated with the mitotic inhibitor die
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eventually as they cannot replicate or repair DNA (Auer et al., 1970). L929 fibroblasts
treated with lower concentrations (5 and 10 µg/ml respectively) of 5-fluoro 2’deoxy
uridine (FUDR) showed protection from cytopathic effects of HSV-1 compared to
untreated HSV-1 control cells. As FUDR treatment time was reduced to 3 hrs. and
concentration of FUDR was low (5µg/ml) survival of cells increased to about 80 to 90% .
Quiescent HSV-1 in L929 cells was rescued by two methods: cells were co-cultured with
Vero cells, or lysed by freeze thaw method and lysate was added to a monolayer of Vero
cells. Plaques were observed after 48 hrs. incubation. Viral plaques on Vero cells
indicated that L929 cells harbored viable virus in them and was rescued from them on
Vero cells. Cell survival decreased by about 30% in L929 cells overlayed with Vero cells
compared to uninfected L929+ Vero cell control. The reduction in cells survival was due
to cytopathic effects of rescued HSV-1 form L929 cells.

The effect of FUDR is reversible by exogenous supply of thymidine or serum in the
medium (Roobol et al., 1984). For future studies, lower concentrations (nM
concentrations) could be used to maintain cells in FUDR containing medium till the end
of the experiment which might keep the cells in the state of arrest for a longer period.
HSV-1 induces apoptosis due to lytic events in non-neuronal cells but becomes latent in
neurons. Viral production of LAT in neurons prevents apoptosis (Branco et al., 2005).
Hoechst staining showed that a minor population of L929 cells was protected from
apoptotic effects of HSV-1 in the presence of FUDR alone as well as FUDR and IFN-
compared to HSV-1 infected control L929 cells at 12 hrs. post-infection. As a high

41

multiplicity of infection (10 moi) was used to induce apoptosis of cells, very few cells
survived HSV-1 infection under these experimental conditions. Another possible reason
could be that cells treated with FUDR reversed the inhibitory effects to resume the
normal cell cycle leading to cell death. However, at 6 hrs. post infection, little difference
was seen in the nuclear morphology except for a few cells which showed atypical
staining (nucleus looked like a bright spot). A flow-cytometric analysis to detect the
presence of apoptotic proteins in L929 cells treated with FUDR and HSV-1 could be
conducted in future. This quantitative analysis performed using antibodies against
apoptotic proteins like caspase 8 or caspase 9 would be useful in detecting if latent HSV1 infection was established in L929 cells (Henderson et al., 2002).

These initial studies were indicative of a silent infection of HSV-1 in L929 cells. The
quiescent infection established in these cells did not lead to establishment of HSV-1
latency (as no LAT transcripts were detected in experimental groups). LAT (latency
associated transcript) is expressed during a latent infection in neurons (Thompson et al
2001). ICP0 is a lytic gene but due to its genomic configuration being anti-sense with
LAT, it is detected during viral reactivation (Perng et al., 2010). In our experimental cells
LAT or ICP0 could not be detected by RT-PCR analysis conducted at 6 and 10 hrs. post
infection. At 16 hrs. post infection LAT was detected in HSV-1 infected L929 control
cells but not in treated cells. Cell counts taken after termination of experiment showed
that number of FUDR treated cells decreased by 20-30% by the end of the experiment.
The sub-population which did not withstand treatment regime might be the one harboring
latent HSV-1 and hence no transcripts were found in the remaining cells. Another
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possible reason could be that there could be other neural lineage specific factors
responsible to establish a latent HSV-1 infection in neurons. Therefore only FUDR and
IFN- γ treatment of cells did not result in establishment of latency as hypothesized. In
natural infection very few neurons (one third) express detectable LAT in latently infected
cells (Su et al., 1999). It may also be possible that a low level of LAT was expressed in
some of the L929 cells treated with FUDR and IFN- which could not be detected by RTPCR analysis (RT-PCR kit detected 1pg -1µg of RNA). In a similar kind of study by Su
et al., (1999) where a quiescent infection of HSV-1 was established in PC-12 cells, LAT
transcripts were detected by southern hybridization in cells where no LAT was found by
RT-PCR analysis. Use of fluorescence in-situ RNA hybridization assay or in-situ PCR
performed at a single cell level would confirm the possibility of low level of LAT
expression.

Fluorescence microscopy for ICP0 displayed a significant difference in the protein
expression in control and treated cells. The number of cells showing ICP0 positive
staining in the FUDR treated cells was in accordance with the previous studies on L929
cells. Auer et al., (1970) using L929 cells showed that only 10% of the population of cells
from an asynchronous culture replicated in the presence of FUDR. Cells were arrested
into G1 and early S-phase. The cell cycle time for L929 cells in culture is approximately
30 hrs. and at this time about 80-90% cells are in G1 and S-phases (Dolznig et al., 2004).
Our results indicated that approximately 17% of the cells in control and 4% of the cells in
treated groups expressed ICP0. In the present study the time at which cells were treated
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with FUDR was the same as used by Auer et al., (1970) 5% cells were probably expected
to show protein expression in presence of FUDR which was observed in our experiment.
A silent infection of HSV-1 was established in L929 cells using FUDR alone and with
IFN-. Latency could not be established under these conditions, although primary
features of a latent infection were observed. First, viable virus in L929 cells was observed
in rescue experiments. Second, a notable difference was seen in the number of cells
expressing ICP0 protein in treated cells compared to HSV-1 infected control. As
discussed earlier, level of LAT expression might be low and thus could not be detected
by RT-PCR. This important feature of latency might be confirmed by analysis of a single
cell using in situ hybridization assay and thus would support further evaluation of the
chromatin state of virus. A chromatin immuno-precipitation assay using L929 cells
treated with FUDR and IFN- would permit a dissection of the virus genome association
with the fibroblast chromatin. A heterochromatin state is observed with viral lytic genes
and a euchromatin state associated with LAT is indicative of viral latency (Bloom et al.,
2010). Chromatin modifiers could be used to treat the cells before infection with HSV-1,
which would support the establishment of latency in these cells. Using the experimental
approach of Vierbuchen et al., (2010), a neuronal phenotype could be induced in
fibroblasts and HSV-1 latency can be studied.
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